Natalie Serkova
Concepts (702)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Magnetic Resonance Spectroscopy | 36 | 2014 | 627 | 2.640 |
Why?
| | Cyclosporine | 20 | 2012 | 256 | 2.490 |
Why?
| | Immunosuppressive Agents | 23 | 2013 | 838 | 2.040 |
Why?
| | Sirolimus | 17 | 2013 | 280 | 1.660 |
Why?
| | Magnetic Resonance Imaging | 25 | 2024 | 3904 | 1.520 |
Why?
| | Piperazines | 6 | 2009 | 375 | 1.140 |
Why?
| | Pyrimidines | 8 | 2017 | 530 | 1.140 |
Why?
| | Metabolomics | 11 | 2021 | 732 | 1.060 |
Why?
| | Brain | 15 | 2026 | 2947 | 1.050 |
Why?
| | Energy Metabolism | 14 | 2019 | 935 | 1.030 |
Why?
| | Glucose | 14 | 2021 | 1048 | 1.030 |
Why?
| | Contrast Media | 6 | 2017 | 497 | 0.980 |
Why?
| | Antineoplastic Agents | 15 | 2022 | 2214 | 0.950 |
Why?
| | Animals | 104 | 2026 | 38030 | 0.850 |
Why?
| | Liver | 12 | 2020 | 1896 | 0.840 |
Why?
| | Biomarkers | 14 | 2019 | 4295 | 0.830 |
Why?
| | Neoplasms | 14 | 2017 | 2906 | 0.780 |
Why?
| | Neoplasms, Experimental | 3 | 2020 | 167 | 0.780 |
Why?
| | Drug Resistance, Neoplasm | 6 | 2017 | 881 | 0.780 |
Why?
| | Cerebellar Neoplasms | 4 | 2025 | 177 | 0.710 |
Why?
| | Medulloblastoma | 4 | 2025 | 215 | 0.690 |
Why?
| | Reperfusion Injury | 11 | 2014 | 293 | 0.670 |
Why?
| | Cell Line, Tumor | 29 | 2026 | 3542 | 0.650 |
Why?
| | Gene Expression Regulation, Neoplastic | 9 | 2025 | 1443 | 0.650 |
Why?
| | Rats | 31 | 2015 | 5584 | 0.630 |
Why?
| | Biomarkers, Tumor | 10 | 2020 | 1321 | 0.610 |
Why?
| | Proton Magnetic Resonance Spectroscopy | 2 | 2019 | 20 | 0.610 |
Why?
| | Multimodal Imaging | 1 | 2020 | 129 | 0.610 |
Why?
| | Protein Kinase Inhibitors | 10 | 2018 | 981 | 0.580 |
Why?
| | Ferrosoferric Oxide | 3 | 2019 | 25 | 0.580 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 5 | 2014 | 127 | 0.560 |
Why?
| | Proto-Oncogene Proteins c-myc | 4 | 2025 | 167 | 0.550 |
Why?
| | Metabolome | 5 | 2019 | 388 | 0.540 |
Why?
| | Mice | 52 | 2026 | 18329 | 0.530 |
Why?
| | Ischemic Preconditioning | 2 | 2009 | 47 | 0.520 |
Why?
| | Nanoparticles | 5 | 2024 | 517 | 0.490 |
Why?
| | Fusion Proteins, bcr-abl | 5 | 2015 | 68 | 0.470 |
Why?
| | Brain Neoplasms | 7 | 2026 | 1329 | 0.470 |
Why?
| | Phospholipids | 7 | 2010 | 214 | 0.470 |
Why?
| | Everolimus | 12 | 2013 | 112 | 0.450 |
Why?
| | Rats, Wistar | 11 | 2010 | 450 | 0.450 |
Why?
| | Hypoxia | 6 | 2015 | 1199 | 0.450 |
Why?
| | Aging | 5 | 2020 | 1969 | 0.430 |
Why?
| | Glutathione | 9 | 2023 | 370 | 0.430 |
Why?
| | Body Fluids | 5 | 2019 | 71 | 0.430 |
Why?
| | Inositol | 4 | 2021 | 25 | 0.430 |
Why?
| | Glutamine | 6 | 2013 | 109 | 0.420 |
Why?
| | Apoptosis | 15 | 2024 | 2440 | 0.410 |
Why?
| | Epilepsy, Post-Traumatic | 1 | 2013 | 5 | 0.410 |
Why?
| | Organ Specificity | 4 | 2013 | 309 | 0.400 |
Why?
| | Nephritis | 1 | 2013 | 22 | 0.400 |
Why?
| | Brain Injuries | 3 | 2014 | 507 | 0.400 |
Why?
| | Positron-Emission Tomography | 10 | 2020 | 343 | 0.390 |
Why?
| | Xenograft Model Antitumor Assays | 12 | 2025 | 934 | 0.390 |
Why?
| | Lupus Nephritis | 2 | 2011 | 67 | 0.390 |
Why?
| | Imatinib Mesylate | 7 | 2014 | 77 | 0.370 |
Why?
| | Mitochondria | 7 | 2014 | 992 | 0.370 |
Why?
| | Rhabdoid Tumor | 2 | 2025 | 102 | 0.360 |
Why?
| | Astrocytes | 5 | 2026 | 228 | 0.360 |
Why?
| | Glioma | 4 | 2024 | 429 | 0.360 |
Why?
| | Leukemia | 2 | 2018 | 246 | 0.360 |
Why?
| | Humans | 78 | 2026 | 145474 | 0.360 |
Why?
| | Blood-Brain Barrier | 3 | 2024 | 160 | 0.350 |
Why?
| | Metabolism | 3 | 2017 | 44 | 0.340 |
Why?
| | Placenta | 3 | 2009 | 786 | 0.340 |
Why?
| | Infratentorial Neoplasms | 2 | 2024 | 71 | 0.340 |
Why?
| | Disease Models, Animal | 16 | 2023 | 4560 | 0.330 |
Why?
| | Reactive Oxygen Species | 5 | 2013 | 611 | 0.330 |
Why?
| | Oxidative Stress | 5 | 2010 | 1356 | 0.330 |
Why?
| | Myocardium | 3 | 2013 | 934 | 0.330 |
Why?
| | Cell Proliferation | 14 | 2025 | 2507 | 0.330 |
Why?
| | Time Factors | 12 | 2013 | 7123 | 0.320 |
Why?
| | Benzamides | 6 | 2009 | 226 | 0.320 |
Why?
| | Kidney | 7 | 2023 | 1497 | 0.320 |
Why?
| | Kidney Diseases | 2 | 2020 | 425 | 0.310 |
Why?
| | Ependymoma | 2 | 2024 | 176 | 0.310 |
Why?
| | Liver Diseases | 2 | 2010 | 305 | 0.300 |
Why?
| | Diagnostic Imaging | 2 | 2011 | 337 | 0.300 |
Why?
| | Molecular Probes | 1 | 2009 | 33 | 0.300 |
Why?
| | Seizures | 1 | 2013 | 483 | 0.300 |
Why?
| | Molecular Targeted Therapy | 2 | 2017 | 439 | 0.290 |
Why?
| | Glucose Transporter Type 1 | 1 | 2009 | 48 | 0.290 |
Why?
| | Liver Transplantation | 2 | 2007 | 826 | 0.290 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 4 | 2017 | 296 | 0.290 |
Why?
| | Silymarin | 4 | 2016 | 147 | 0.290 |
Why?
| | Drug Monitoring | 3 | 2013 | 401 | 0.280 |
Why?
| | Prostatic Neoplasms | 5 | 2016 | 978 | 0.280 |
Why?
| | Lactic Acid | 7 | 2013 | 295 | 0.280 |
Why?
| | Complement C3b | 2 | 2023 | 29 | 0.280 |
Why?
| | Spermine | 1 | 2008 | 29 | 0.280 |
Why?
| | K562 Cells | 4 | 2009 | 92 | 0.270 |
Why?
| | Citric Acid | 1 | 2008 | 33 | 0.270 |
Why?
| | Adenosine Triphosphate | 6 | 2009 | 500 | 0.270 |
Why?
| | Graft Rejection | 5 | 2010 | 521 | 0.260 |
Why?
| | Adaptation, Physiological | 2 | 2009 | 560 | 0.260 |
Why?
| | Hibernation | 2 | 2014 | 82 | 0.260 |
Why?
| | Drug Design | 2 | 2007 | 175 | 0.260 |
Why?
| | Kidney Transplantation | 4 | 2010 | 712 | 0.250 |
Why?
| | Head and Neck Neoplasms | 3 | 2019 | 561 | 0.250 |
Why?
| | Signal Transduction | 12 | 2026 | 5216 | 0.250 |
Why?
| | Tomography, X-Ray Computed | 3 | 2020 | 2769 | 0.250 |
Why?
| | Prostate | 1 | 2008 | 158 | 0.250 |
Why?
| | Creatine | 3 | 2021 | 63 | 0.250 |
Why?
| | Altitude | 3 | 2009 | 463 | 0.240 |
Why?
| | Choline | 2 | 2009 | 137 | 0.240 |
Why?
| | Rats, Sprague-Dawley | 11 | 2015 | 2524 | 0.240 |
Why?
| | Liver Failure | 1 | 2007 | 83 | 0.240 |
Why?
| | Neural Cell Adhesion Molecules | 1 | 2026 | 38 | 0.240 |
Why?
| | Drug Therapy | 1 | 2006 | 84 | 0.230 |
Why?
| | Interleukin-1beta | 1 | 2008 | 389 | 0.230 |
Why?
| | Pneumonia | 2 | 2011 | 636 | 0.230 |
Why?
| | Dietary Supplements | 3 | 2023 | 583 | 0.230 |
Why?
| | Fibroblast Growth Factor 2 | 1 | 2026 | 94 | 0.230 |
Why?
| | Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2026 | 58 | 0.230 |
Why?
| | Nanomedicine | 2 | 2024 | 47 | 0.230 |
Why?
| | Blotting, Western | 6 | 2019 | 1179 | 0.230 |
Why?
| | Transcription, Genetic | 4 | 2025 | 1454 | 0.230 |
Why?
| | Myocardial Reperfusion Injury | 2 | 2003 | 139 | 0.230 |
Why?
| | Male | 47 | 2024 | 72842 | 0.230 |
Why?
| | fms-Like Tyrosine Kinase 3 | 2 | 2016 | 51 | 0.230 |
Why?
| | Cyclin-Dependent Kinase 8 | 1 | 2025 | 50 | 0.220 |
Why?
| | Colorectal Neoplasms | 4 | 2018 | 866 | 0.220 |
Why?
| | Neovascularization, Pathologic | 4 | 2018 | 286 | 0.220 |
Why?
| | SMARCB1 Protein | 1 | 2025 | 34 | 0.220 |
Why?
| | Sex Characteristics | 1 | 2010 | 782 | 0.220 |
Why?
| | Sirtuin 2 | 1 | 2025 | 28 | 0.220 |
Why?
| | Protein Kinases | 2 | 2004 | 312 | 0.220 |
Why?
| | Macrolides | 2 | 2013 | 67 | 0.220 |
Why?
| | Protein-Tyrosine Kinases | 3 | 2014 | 431 | 0.210 |
Why?
| | Brain Injuries, Traumatic | 2 | 2023 | 453 | 0.210 |
Why?
| | Drug Interactions | 6 | 2012 | 405 | 0.210 |
Why?
| | Positive Transcriptional Elongation Factor B | 1 | 2024 | 29 | 0.210 |
Why?
| | Tumor Suppressor Protein p53 | 2 | 2022 | 534 | 0.210 |
Why?
| | Protein Biosynthesis | 2 | 2025 | 452 | 0.210 |
Why?
| | Microbubbles | 1 | 2024 | 53 | 0.210 |
Why?
| | Dose-Response Relationship, Drug | 10 | 2012 | 2028 | 0.200 |
Why?
| | Cell Transformation, Neoplastic | 3 | 2015 | 337 | 0.200 |
Why?
| | Neurotoxicity Syndromes | 1 | 2004 | 40 | 0.200 |
Why?
| | Chromatography, High Pressure Liquid | 5 | 2009 | 592 | 0.200 |
Why?
| | Sepsis | 4 | 2013 | 664 | 0.200 |
Why?
| | Organ Transplantation | 2 | 2004 | 251 | 0.200 |
Why?
| | Obesity | 3 | 2006 | 3116 | 0.200 |
Why?
| | TOR Serine-Threonine Kinases | 6 | 2025 | 454 | 0.200 |
Why?
| | Glycolysis | 4 | 2010 | 340 | 0.200 |
Why?
| | Autophagy | 2 | 2018 | 291 | 0.190 |
Why?
| | Receptors, Estrogen | 1 | 2026 | 401 | 0.190 |
Why?
| | Autolysis | 1 | 2003 | 3 | 0.190 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2008 | 1217 | 0.190 |
Why?
| | Glomerulonephritis | 1 | 2023 | 44 | 0.190 |
Why?
| | Fatty Liver | 1 | 2005 | 253 | 0.190 |
Why?
| | Carcinoma, Hepatocellular | 2 | 2020 | 372 | 0.190 |
Why?
| | DNA Repair | 2 | 2024 | 254 | 0.180 |
Why?
| | Lung Transplantation | 3 | 2000 | 332 | 0.180 |
Why?
| | Phosphates | 2 | 2001 | 177 | 0.180 |
Why?
| | Deoxycytidine | 2 | 2017 | 220 | 0.180 |
Why?
| | In Vitro Techniques | 5 | 2016 | 1048 | 0.180 |
Why?
| | Antineoplastic Agents, Phytogenic | 2 | 2013 | 178 | 0.180 |
Why?
| | Colonic Neoplasms | 3 | 2013 | 257 | 0.180 |
Why?
| | Proto-Oncogene Proteins c-mdm2 | 1 | 2022 | 67 | 0.170 |
Why?
| | Carbon Isotopes | 3 | 2009 | 143 | 0.170 |
Why?
| | Mice, Nude | 8 | 2016 | 679 | 0.170 |
Why?
| | Radiation Tolerance | 1 | 2022 | 103 | 0.170 |
Why?
| | Chemoradiotherapy | 2 | 2019 | 239 | 0.170 |
Why?
| | Specimen Handling | 1 | 2003 | 182 | 0.170 |
Why?
| | Image Processing, Computer-Assisted | 3 | 2019 | 779 | 0.170 |
Why?
| | Gene Expression Regulation | 4 | 2019 | 2597 | 0.170 |
Why?
| | Hydroxamic Acids | 2 | 2011 | 94 | 0.170 |
Why?
| | Photoacoustic Techniques | 1 | 2020 | 5 | 0.170 |
Why?
| | Tendinopathy | 1 | 2021 | 32 | 0.170 |
Why?
| | Magnetite Nanoparticles | 2 | 2011 | 27 | 0.160 |
Why?
| | Lung | 8 | 2018 | 4106 | 0.160 |
Why?
| | Anticarcinogenic Agents | 2 | 2011 | 62 | 0.160 |
Why?
| | Tomography, Emission-Computed, Single-Photon | 1 | 2020 | 104 | 0.160 |
Why?
| | Mass Spectrometry | 4 | 2011 | 730 | 0.160 |
Why?
| | Heat-Shock Proteins | 3 | 2006 | 139 | 0.160 |
Why?
| | Insulin Resistance | 2 | 2019 | 1244 | 0.160 |
Why?
| | Polycomb Repressive Complex 1 | 1 | 2020 | 66 | 0.160 |
Why?
| | Mammary Glands, Animal | 2 | 2014 | 128 | 0.160 |
Why?
| | Transcriptional Elongation Factors | 1 | 2020 | 39 | 0.150 |
Why?
| | Particle Accelerators | 1 | 2019 | 9 | 0.150 |
Why?
| | Osteoarthritis | 1 | 2022 | 200 | 0.150 |
Why?
| | Camptothecin | 2 | 2013 | 138 | 0.150 |
Why?
| | Electromagnetic Phenomena | 1 | 2019 | 24 | 0.150 |
Why?
| | Scavenger Receptors, Class A | 1 | 2019 | 12 | 0.150 |
Why?
| | Anterior Cruciate Ligament Injuries | 1 | 2022 | 218 | 0.150 |
Why?
| | Heart | 1 | 2003 | 626 | 0.150 |
Why?
| | Histone Deacetylase Inhibitors | 2 | 2011 | 218 | 0.150 |
Why?
| | Brain Chemistry | 1 | 2000 | 119 | 0.150 |
Why?
| | Chromosomes, Human, Pair 1 | 1 | 2019 | 80 | 0.150 |
Why?
| | Complement Factor H | 1 | 2020 | 79 | 0.150 |
Why?
| | Lactation | 2 | 2014 | 193 | 0.150 |
Why?
| | Macrophages, Peritoneal | 1 | 2019 | 89 | 0.150 |
Why?
| | Perfusion | 3 | 2009 | 251 | 0.150 |
Why?
| | Precursor Cells, B-Lymphoid | 2 | 2017 | 41 | 0.150 |
Why?
| | Fatty Acids | 2 | 2015 | 457 | 0.150 |
Why?
| | Endoplasmic Reticulum Stress | 3 | 2014 | 118 | 0.140 |
Why?
| | Fluorodeoxyglucose F18 | 2 | 2021 | 161 | 0.140 |
Why?
| | Inflammation | 4 | 2024 | 2878 | 0.140 |
Why?
| | Receptor, EphB4 | 1 | 2019 | 33 | 0.140 |
Why?
| | Ephrin-B2 | 1 | 2019 | 45 | 0.140 |
Why?
| | Tumor Cells, Cultured | 4 | 2025 | 886 | 0.140 |
Why?
| | Lipogenesis | 2 | 2016 | 62 | 0.140 |
Why?
| | Angiogenesis Inhibitors | 2 | 2011 | 238 | 0.140 |
Why?
| | Estrogens | 2 | 2026 | 367 | 0.140 |
Why?
| | Whey Proteins | 1 | 2018 | 9 | 0.140 |
Why?
| | Neoplasm Proteins | 2 | 2020 | 441 | 0.140 |
Why?
| | Smad4 Protein | 1 | 2018 | 34 | 0.140 |
Why?
| | Glucose Clamp Technique | 1 | 2019 | 199 | 0.140 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 5 | 2014 | 1963 | 0.140 |
Why?
| | Phosphocreatine | 3 | 2004 | 44 | 0.140 |
Why?
| | Salivary Gland Neoplasms | 1 | 2018 | 39 | 0.130 |
Why?
| | Anilides | 1 | 2018 | 84 | 0.130 |
Why?
| | Polyenes | 1 | 1997 | 17 | 0.130 |
Why?
| | Histones | 2 | 2020 | 666 | 0.130 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 3 | 2013 | 254 | 0.130 |
Why?
| | Tumor Microenvironment | 2 | 2019 | 734 | 0.130 |
Why?
| | Kinetics | 3 | 2009 | 1567 | 0.130 |
Why?
| | Cells, Cultured | 6 | 2019 | 4148 | 0.130 |
Why?
| | Rats, Zucker | 3 | 2006 | 32 | 0.130 |
Why?
| | Tracheal Stenosis | 1 | 2018 | 39 | 0.130 |
Why?
| | Mucin-1 | 1 | 2017 | 21 | 0.130 |
Why?
| | Acute Lung Injury | 2 | 2011 | 305 | 0.130 |
Why?
| | Phosphorylation | 4 | 2013 | 1707 | 0.130 |
Why?
| | Folic Acid Deficiency | 1 | 2017 | 49 | 0.130 |
Why?
| | Female | 29 | 2026 | 78844 | 0.130 |
Why?
| | Lactates | 3 | 2006 | 82 | 0.130 |
Why?
| | PTEN Phosphohydrolase | 1 | 2018 | 165 | 0.130 |
Why?
| | Drug Synergism | 5 | 2013 | 354 | 0.120 |
Why?
| | Neuroprotective Agents | 1 | 2018 | 147 | 0.120 |
Why?
| | Adenosine Diphosphate | 2 | 2009 | 83 | 0.120 |
Why?
| | Fibroblasts | 2 | 2016 | 1025 | 0.120 |
Why?
| | Macrophages | 3 | 2019 | 1507 | 0.120 |
Why?
| | Quinazolines | 2 | 2008 | 266 | 0.120 |
Why?
| | Inflammation Mediators | 1 | 2019 | 506 | 0.120 |
Why?
| | Ataxia Telangiectasia Mutated Proteins | 1 | 2016 | 69 | 0.120 |
Why?
| | Tissue Extracts | 2 | 2009 | 19 | 0.120 |
Why?
| | Gene Expression Regulation, Leukemic | 1 | 2016 | 56 | 0.120 |
Why?
| | Heme Oxygenase (Decyclizing) | 2 | 2013 | 21 | 0.120 |
Why?
| | Vascular Endothelial Growth Factor Receptor-2 | 3 | 2013 | 86 | 0.120 |
Why?
| | Hematopoiesis | 1 | 2017 | 193 | 0.120 |
Why?
| | Alcohol Oxidoreductases | 1 | 2016 | 61 | 0.120 |
Why?
| | Pancreatic Neoplasms | 2 | 2017 | 928 | 0.120 |
Why?
| | Glucosephosphate Dehydrogenase | 1 | 2016 | 70 | 0.120 |
Why?
| | Transcription Factors | 5 | 2014 | 1734 | 0.120 |
Why?
| | Folic Acid | 1 | 2017 | 198 | 0.120 |
Why?
| | Creatinine | 4 | 2005 | 515 | 0.120 |
Why?
| | Familial Primary Pulmonary Hypertension | 1 | 2016 | 196 | 0.120 |
Why?
| | Lipid Peroxidation | 3 | 2006 | 167 | 0.120 |
Why?
| | Flow Cytometry | 2 | 2010 | 1162 | 0.110 |
Why?
| | Blood Glucose | 4 | 2019 | 2341 | 0.110 |
Why?
| | Fluorouracil | 2 | 2024 | 231 | 0.110 |
Why?
| | Liver Neoplasms | 2 | 2020 | 776 | 0.110 |
Why?
| | Neuroglia | 1 | 1996 | 173 | 0.110 |
Why?
| | Radiography | 2 | 2008 | 852 | 0.110 |
Why?
| | Drug Delivery Systems | 3 | 2024 | 381 | 0.110 |
Why?
| | Nuclear Magnetic Resonance, Biomolecular | 4 | 2011 | 345 | 0.110 |
Why?
| | Pyrazoles | 2 | 2010 | 517 | 0.110 |
Why?
| | Lipid Metabolism | 4 | 2019 | 529 | 0.110 |
Why?
| | Methylamines | 2 | 2005 | 39 | 0.110 |
Why?
| | Paracrine Communication | 1 | 2015 | 67 | 0.110 |
Why?
| | Hypothermia, Induced | 2 | 2006 | 95 | 0.110 |
Why?
| | Hernias, Diaphragmatic, Congenital | 1 | 2018 | 221 | 0.110 |
Why?
| | Oligomycins | 1 | 2014 | 7 | 0.110 |
Why?
| | Proto-Oncogene Proteins c-akt | 3 | 2018 | 440 | 0.110 |
Why?
| | Brain Concussion | 1 | 2023 | 644 | 0.110 |
Why?
| | Mitochondrial Proton-Translocating ATPases | 1 | 2014 | 23 | 0.110 |
Why?
| | Pentacyclic Triterpenes | 1 | 2014 | 12 | 0.110 |
Why?
| | Fatty Acids, Unsaturated | 2 | 2005 | 96 | 0.110 |
Why?
| | Nuclear Proteins | 2 | 2023 | 740 | 0.110 |
Why?
| | Myocardial Infarction | 1 | 2002 | 1210 | 0.110 |
Why?
| | Models, Animal | 2 | 2009 | 393 | 0.110 |
Why?
| | Homeostasis | 1 | 2018 | 642 | 0.110 |
Why?
| | Ferric Compounds | 1 | 2014 | 54 | 0.100 |
Why?
| | ras Proteins | 2 | 2013 | 150 | 0.100 |
Why?
| | Rats, Inbred Lew | 4 | 2010 | 105 | 0.100 |
Why?
| | Hypertension, Pulmonary | 2 | 2016 | 1957 | 0.100 |
Why?
| | Fatty Acid Synthase, Type I | 1 | 2014 | 11 | 0.100 |
Why?
| | Leukotrienes | 1 | 2014 | 28 | 0.100 |
Why?
| | Lipoxygenase Inhibitors | 1 | 2014 | 34 | 0.100 |
Why?
| | CRISPR-Cas Systems | 2 | 2025 | 166 | 0.100 |
Why?
| | Convulsants | 1 | 2013 | 8 | 0.100 |
Why?
| | Dextrans | 2 | 2014 | 84 | 0.100 |
Why?
| | Kainic Acid | 1 | 2013 | 33 | 0.100 |
Why?
| | Pyridines | 1 | 2018 | 609 | 0.100 |
Why?
| | NAD | 2 | 2004 | 79 | 0.100 |
Why?
| | Propranolol | 1 | 2013 | 44 | 0.100 |
Why?
| | Treatment Outcome | 9 | 2024 | 11772 | 0.100 |
Why?
| | Urothelium | 1 | 2013 | 33 | 0.100 |
Why?
| | Brain Edema | 1 | 2013 | 62 | 0.100 |
Why?
| | Indoles | 2 | 2015 | 507 | 0.100 |
Why?
| | Azoxymethane | 1 | 2013 | 18 | 0.100 |
Why?
| | Cell Survival | 4 | 2016 | 1100 | 0.100 |
Why?
| | Mice, Inbred BALB C | 4 | 2019 | 1261 | 0.100 |
Why?
| | Unfolded Protein Response | 1 | 2013 | 58 | 0.100 |
Why?
| | Breast Neoplasms | 1 | 2026 | 2382 | 0.100 |
Why?
| | Disease Progression | 6 | 2026 | 2864 | 0.100 |
Why?
| | Grape Seed Extract | 1 | 2013 | 29 | 0.100 |
Why?
| | Neurons | 2 | 2026 | 1649 | 0.100 |
Why?
| | Prognosis | 4 | 2017 | 4316 | 0.100 |
Why?
| | Fetal Growth Retardation | 1 | 2019 | 593 | 0.090 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2019 | 977 | 0.090 |
Why?
| | Equipment Design | 2 | 2019 | 525 | 0.090 |
Why?
| | Phytic Acid | 1 | 2012 | 35 | 0.090 |
Why?
| | Triple Negative Breast Neoplasms | 1 | 2015 | 218 | 0.090 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 2 | 2015 | 109 | 0.090 |
Why?
| | Diffusion Magnetic Resonance Imaging | 1 | 2013 | 155 | 0.090 |
Why?
| | Severity of Illness Index | 2 | 2013 | 2930 | 0.090 |
Why?
| | Thiophenes | 1 | 2013 | 117 | 0.090 |
Why?
| | Metabolic Diseases | 1 | 2013 | 114 | 0.090 |
Why?
| | Reference Values | 3 | 2019 | 798 | 0.090 |
Why?
| | DNA-Binding Proteins | 3 | 2016 | 1480 | 0.090 |
Why?
| | Image Enhancement | 2 | 2010 | 200 | 0.090 |
Why?
| | Adrenergic beta-Antagonists | 1 | 2013 | 252 | 0.090 |
Why?
| | Pregnancy | 6 | 2019 | 7202 | 0.090 |
Why?
| | Shock, Hemorrhagic | 1 | 2014 | 199 | 0.090 |
Why?
| | Insulin | 3 | 2019 | 2512 | 0.090 |
Why?
| | Mice, Transgenic | 6 | 2015 | 2188 | 0.090 |
Why?
| | Radionuclide Imaging | 1 | 2012 | 115 | 0.090 |
Why?
| | Proto-Oncogene Proteins | 2 | 2013 | 624 | 0.090 |
Why?
| | HSP70 Heat-Shock Proteins | 3 | 2010 | 75 | 0.090 |
Why?
| | Quinolines | 1 | 2013 | 190 | 0.090 |
Why?
| | RNA Polymerase II | 2 | 2025 | 350 | 0.090 |
Why?
| | Temperature | 3 | 2014 | 633 | 0.090 |
Why?
| | Isotope Labeling | 1 | 2012 | 82 | 0.090 |
Why?
| | Calcineurin | 1 | 2012 | 105 | 0.080 |
Why?
| | Tissue Distribution | 2 | 2003 | 335 | 0.080 |
Why?
| | Proteasome Inhibitors | 1 | 2011 | 41 | 0.080 |
Why?
| | Mice, Inbred NOD | 3 | 2019 | 613 | 0.080 |
Why?
| | Urinary Bladder | 1 | 2013 | 195 | 0.080 |
Why?
| | Boronic Acids | 1 | 2011 | 36 | 0.080 |
Why?
| | Reproducibility of Results | 5 | 2019 | 3413 | 0.080 |
Why?
| | Feasibility Studies | 2 | 2019 | 1111 | 0.080 |
Why?
| | Models, Biological | 5 | 2013 | 1764 | 0.080 |
Why?
| | Glioblastoma | 1 | 2014 | 353 | 0.080 |
Why?
| | Sarcoma | 1 | 2013 | 207 | 0.080 |
Why?
| | Tacrolimus | 1 | 2012 | 196 | 0.080 |
Why?
| | Nucleotides | 2 | 2017 | 129 | 0.080 |
Why?
| | Sciuridae | 2 | 2014 | 152 | 0.080 |
Why?
| | Tandem Mass Spectrometry | 2 | 2014 | 572 | 0.080 |
Why?
| | Protease Inhibitors | 1 | 2011 | 102 | 0.080 |
Why?
| | Antibodies, Monoclonal | 3 | 2023 | 1505 | 0.080 |
Why?
| | Benzimidazoles | 1 | 2011 | 189 | 0.080 |
Why?
| | Nitric Oxide Synthase Type II | 1 | 2010 | 162 | 0.080 |
Why?
| | Phosphatidylinositol 3-Kinases | 3 | 2018 | 382 | 0.080 |
Why?
| | Cell Movement | 3 | 2026 | 959 | 0.080 |
Why?
| | Complement C3-C5 Convertases | 1 | 2010 | 21 | 0.080 |
Why?
| | Hydroxybutyrates | 2 | 2010 | 15 | 0.080 |
Why?
| | Heart Ventricles | 1 | 2015 | 756 | 0.080 |
Why?
| | Pyrazines | 1 | 2011 | 94 | 0.080 |
Why?
| | Electroencephalography | 1 | 2013 | 561 | 0.080 |
Why?
| | Cricetulus | 1 | 2010 | 118 | 0.080 |
Why?
| | CHO Cells | 1 | 2010 | 169 | 0.080 |
Why?
| | Epigenomics | 2 | 2020 | 114 | 0.080 |
Why?
| | TRPP Cation Channels | 1 | 2010 | 74 | 0.080 |
Why?
| | Fatty Acids, Monounsaturated | 2 | 2010 | 55 | 0.080 |
Why?
| | Cricetinae | 1 | 2010 | 305 | 0.080 |
Why?
| | Adult | 10 | 2013 | 40777 | 0.080 |
Why?
| | Cognition Disorders | 1 | 2014 | 541 | 0.080 |
Why?
| | Analysis of Variance | 2 | 2010 | 1300 | 0.070 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2016 | 686 | 0.070 |
Why?
| | Neoplasm Transplantation | 3 | 2019 | 246 | 0.070 |
Why?
| | ErbB Receptors | 2 | 2015 | 635 | 0.070 |
Why?
| | Ribose | 1 | 2009 | 22 | 0.070 |
Why?
| | Mice, Knockout | 5 | 2020 | 3124 | 0.070 |
Why?
| | Cysts | 1 | 2010 | 112 | 0.070 |
Why?
| | Dinoprost | 1 | 2009 | 49 | 0.070 |
Why?
| | Cell Extracts | 1 | 2009 | 19 | 0.070 |
Why?
| | RNA, Neoplasm | 1 | 2009 | 83 | 0.070 |
Why?
| | Intestine, Small | 1 | 2010 | 167 | 0.070 |
Why?
| | Percussion | 1 | 2008 | 2 | 0.070 |
Why?
| | Gas Chromatography-Mass Spectrometry | 1 | 2009 | 124 | 0.070 |
Why?
| | Deoxyglucose | 1 | 2009 | 51 | 0.070 |
Why?
| | Surgical Equipment | 1 | 2008 | 8 | 0.070 |
Why?
| | History, 21st Century | 1 | 2009 | 222 | 0.070 |
Why?
| | Mutation | 3 | 2020 | 4075 | 0.070 |
Why?
| | Alanine | 2 | 2013 | 169 | 0.070 |
Why?
| | History, 20th Century | 1 | 2009 | 328 | 0.070 |
Why?
| | Sulfonamides | 2 | 2011 | 583 | 0.070 |
Why?
| | Receptor, ErbB-3 | 1 | 2008 | 48 | 0.070 |
Why?
| | Macaca fascicularis | 4 | 2000 | 70 | 0.070 |
Why?
| | Complement C3d | 2 | 2023 | 62 | 0.070 |
Why?
| | Systems Biology | 1 | 2009 | 69 | 0.070 |
Why?
| | Body Weight | 4 | 2012 | 971 | 0.070 |
Why?
| | Oxidation-Reduction | 3 | 2016 | 1067 | 0.070 |
Why?
| | Oxygen | 2 | 2010 | 978 | 0.070 |
Why?
| | Protein Transport | 1 | 2009 | 442 | 0.060 |
Why?
| | DNA | 2 | 2009 | 1435 | 0.060 |
Why?
| | Lymphocytes | 1 | 2009 | 376 | 0.060 |
Why?
| | Area Under Curve | 1 | 2008 | 331 | 0.060 |
Why?
| | Triglycerides | 2 | 2010 | 520 | 0.060 |
Why?
| | Critical Illness | 2 | 2011 | 900 | 0.060 |
Why?
| | Heart-Assist Devices | 1 | 2013 | 568 | 0.060 |
Why?
| | Heterografts | 2 | 2019 | 143 | 0.060 |
Why?
| | Tritium | 1 | 2006 | 67 | 0.060 |
Why?
| | MicroRNAs | 1 | 2013 | 686 | 0.060 |
Why?
| | X-Ray Microtomography | 2 | 2021 | 108 | 0.060 |
Why?
| | Oxidative Phosphorylation | 2 | 2005 | 209 | 0.060 |
Why?
| | Polycystic Kidney, Autosomal Dominant | 1 | 2010 | 235 | 0.060 |
Why?
| | Nitrogen | 1 | 2007 | 125 | 0.060 |
Why?
| | Up-Regulation | 2 | 2006 | 847 | 0.060 |
Why?
| | Age Factors | 2 | 2011 | 3342 | 0.060 |
Why?
| | Leukocytes, Mononuclear | 1 | 2009 | 574 | 0.060 |
Why?
| | Body Temperature | 1 | 2007 | 227 | 0.060 |
Why?
| | Chromatin | 2 | 2020 | 553 | 0.060 |
Why?
| | Maximum Tolerated Dose | 3 | 2013 | 210 | 0.060 |
Why?
| | ROC Curve | 1 | 2008 | 617 | 0.060 |
Why?
| | Piperidines | 1 | 2007 | 222 | 0.060 |
Why?
| | Mice, Inbred C57BL | 5 | 2018 | 5983 | 0.060 |
Why?
| | Heat-Shock Response | 1 | 2006 | 77 | 0.060 |
Why?
| | Cyclin-Dependent Kinase 9 | 1 | 2025 | 18 | 0.060 |
Why?
| | Medical Oncology | 1 | 2009 | 339 | 0.060 |
Why?
| | Liver Failure, Acute | 1 | 2006 | 68 | 0.060 |
Why?
| | Allantoin | 1 | 2005 | 2 | 0.060 |
Why?
| | Betaine | 1 | 2005 | 67 | 0.060 |
Why?
| | Deuterium | 1 | 2005 | 100 | 0.060 |
Why?
| | Cell Differentiation | 2 | 2025 | 2046 | 0.060 |
Why?
| | Survival Rate | 3 | 2019 | 2090 | 0.060 |
Why?
| | Lung Injury | 1 | 2008 | 244 | 0.050 |
Why?
| | Glutamic Acid | 2 | 2010 | 255 | 0.050 |
Why?
| | Alcohol Drinking | 1 | 2012 | 837 | 0.050 |
Why?
| | Methionine | 1 | 2005 | 161 | 0.050 |
Why?
| | Reference Standards | 2 | 2019 | 177 | 0.050 |
Why?
| | Glutamates | 1 | 2004 | 66 | 0.050 |
Why?
| | Seasons | 1 | 2007 | 538 | 0.050 |
Why?
| | Mitochondrial Encephalomyopathies | 1 | 2004 | 9 | 0.050 |
Why?
| | Free Radical Scavengers | 1 | 2004 | 82 | 0.050 |
Why?
| | Heart Rate | 2 | 2009 | 855 | 0.050 |
Why?
| | Uric Acid | 1 | 2005 | 167 | 0.050 |
Why?
| | Dacarbazine | 2 | 2014 | 100 | 0.050 |
Why?
| | HSP72 Heat-Shock Proteins | 1 | 2003 | 31 | 0.050 |
Why?
| | Biological Transport | 2 | 2015 | 424 | 0.050 |
Why?
| | Gene Expression Profiling | 3 | 2019 | 1767 | 0.050 |
Why?
| | Cholesterol | 1 | 2005 | 408 | 0.050 |
Why?
| | Chromosomes | 1 | 2024 | 106 | 0.050 |
Why?
| | Calcineurin Inhibitors | 1 | 2003 | 69 | 0.050 |
Why?
| | Hot Temperature | 1 | 2006 | 396 | 0.050 |
Why?
| | Injections, Intravenous | 1 | 2003 | 197 | 0.050 |
Why?
| | Proteins | 1 | 2009 | 1023 | 0.050 |
Why?
| | Hypoxia-Ischemia, Brain | 1 | 2004 | 49 | 0.050 |
Why?
| | RNA, Small Interfering | 2 | 2016 | 637 | 0.050 |
Why?
| | Cardiac Output | 1 | 2003 | 179 | 0.050 |
Why?
| | Lipids | 2 | 2021 | 707 | 0.050 |
Why?
| | Acetylcysteine | 1 | 2004 | 139 | 0.050 |
Why?
| | Gliosis | 1 | 2023 | 30 | 0.050 |
Why?
| | Coronary Circulation | 1 | 2003 | 134 | 0.050 |
Why?
| | Drug Carriers | 1 | 2024 | 136 | 0.050 |
Why?
| | Mitochondria, Liver | 1 | 2003 | 70 | 0.050 |
Why?
| | Tyrosine | 1 | 2023 | 217 | 0.050 |
Why?
| | Necrosis | 3 | 2010 | 244 | 0.050 |
Why?
| | Aged | 5 | 2013 | 26153 | 0.050 |
Why?
| | Models, Cardiovascular | 1 | 2003 | 196 | 0.050 |
Why?
| | Protein Tyrosine Phosphatases | 1 | 2023 | 167 | 0.050 |
Why?
| | Mitochondria, Heart | 1 | 2003 | 107 | 0.050 |
Why?
| | Rupture | 1 | 2022 | 91 | 0.050 |
Why?
| | Anesthetics, Intravenous | 1 | 2002 | 69 | 0.050 |
Why?
| | Isoflurane | 1 | 2002 | 41 | 0.050 |
Why?
| | Liposomes | 1 | 2024 | 262 | 0.040 |
Why?
| | Child | 4 | 2024 | 22707 | 0.040 |
Why?
| | Reperfusion | 1 | 2002 | 54 | 0.040 |
Why?
| | Anterior Cruciate Ligament | 1 | 2022 | 101 | 0.040 |
Why?
| | Adenocarcinoma | 1 | 2009 | 925 | 0.040 |
Why?
| | Wounds and Injuries | 1 | 2010 | 961 | 0.040 |
Why?
| | Oxaloacetic Acid | 1 | 2001 | 4 | 0.040 |
Why?
| | Tumor Burden | 2 | 2014 | 325 | 0.040 |
Why?
| | AMP-Activated Protein Kinases | 2 | 2013 | 192 | 0.040 |
Why?
| | Aspartic Acid | 1 | 2001 | 88 | 0.040 |
Why?
| | Succinic Acid | 2 | 2013 | 46 | 0.040 |
Why?
| | Tibia | 1 | 2022 | 176 | 0.040 |
Why?
| | Microsomes, Liver | 1 | 2001 | 85 | 0.040 |
Why?
| | Teratoma | 1 | 2022 | 124 | 0.040 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2023 | 456 | 0.040 |
Why?
| | Drug Therapy, Combination | 3 | 2016 | 1044 | 0.040 |
Why?
| | Random Allocation | 3 | 2006 | 365 | 0.040 |
Why?
| | Coronary Vessels | 1 | 2002 | 246 | 0.040 |
Why?
| | Glomerulonephritis, Membranoproliferative | 1 | 2020 | 25 | 0.040 |
Why?
| | Positron Emission Tomography Computed Tomography | 1 | 2021 | 117 | 0.040 |
Why?
| | Middle Aged | 6 | 2016 | 36215 | 0.040 |
Why?
| | Pulmonary Alveoli | 1 | 2002 | 385 | 0.040 |
Why?
| | Brain Stem Neoplasms | 1 | 2020 | 87 | 0.040 |
Why?
| | Ligands | 2 | 2012 | 665 | 0.040 |
Why?
| | Tunica Intima | 1 | 2000 | 78 | 0.040 |
Why?
| | Phenotype | 3 | 2016 | 3155 | 0.040 |
Why?
| | Hematinics | 1 | 2019 | 22 | 0.040 |
Why?
| | Astrocytoma | 1 | 2020 | 130 | 0.040 |
Why?
| | gamma-Aminobutyric Acid | 1 | 2001 | 194 | 0.040 |
Why?
| | Heart Failure | 1 | 2013 | 2326 | 0.040 |
Why?
| | Enzyme Activation | 2 | 2013 | 762 | 0.040 |
Why?
| | Sheep, Domestic | 1 | 2019 | 34 | 0.040 |
Why?
| | Fluorescent Antibody Technique | 2 | 2013 | 365 | 0.040 |
Why?
| | Mice, SCID | 1 | 2019 | 369 | 0.040 |
Why?
| | Mouth Mucosa | 1 | 2019 | 85 | 0.040 |
Why?
| | Drug Administration Schedule | 2 | 2013 | 782 | 0.040 |
Why?
| | Survival Analysis | 2 | 2016 | 1374 | 0.030 |
Why?
| | Chromatography, Liquid | 1 | 2000 | 450 | 0.030 |
Why?
| | Transplantation, Homologous | 1 | 2000 | 418 | 0.030 |
Why?
| | Mifepristone | 1 | 2018 | 53 | 0.030 |
Why?
| | Knee Joint | 1 | 2022 | 428 | 0.030 |
Why?
| | Carcinoma, Adenoid Cystic | 1 | 2018 | 19 | 0.030 |
Why?
| | Salivary Glands | 1 | 2018 | 36 | 0.030 |
Why?
| | Pregnancy Complications | 1 | 2004 | 602 | 0.030 |
Why?
| | Radiology, Interventional | 1 | 2019 | 49 | 0.030 |
Why?
| | Anthropometry | 1 | 2019 | 206 | 0.030 |
Why?
| | NF-kappa B | 2 | 2013 | 666 | 0.030 |
Why?
| | Lysine | 1 | 2020 | 305 | 0.030 |
Why?
| | Breast | 1 | 2019 | 156 | 0.030 |
Why?
| | Immunohistochemistry | 2 | 2012 | 1716 | 0.030 |
Why?
| | Amino Acids | 1 | 2002 | 519 | 0.030 |
Why?
| | Phantoms, Imaging | 1 | 2019 | 159 | 0.030 |
Why?
| | Citric Acid Cycle | 1 | 1997 | 58 | 0.030 |
Why?
| | Cell Size | 1 | 1997 | 92 | 0.030 |
Why?
| | Robotics | 1 | 2019 | 90 | 0.030 |
Why?
| | Digoxin | 1 | 2017 | 27 | 0.030 |
Why?
| | Weight Gain | 1 | 2001 | 561 | 0.030 |
Why?
| | Pentose Phosphate Pathway | 1 | 2017 | 55 | 0.030 |
Why?
| | Lung Neoplasms | 1 | 2010 | 2664 | 0.030 |
Why?
| | Cytosol | 1 | 1997 | 213 | 0.030 |
Why?
| | Diet, High-Fat | 1 | 2018 | 266 | 0.030 |
Why?
| | Vascular Endothelial Growth Factor Receptor-1 | 2 | 2010 | 74 | 0.030 |
Why?
| | Rabbits | 1 | 2018 | 652 | 0.030 |
Why?
| | Cysteine | 1 | 2018 | 211 | 0.030 |
Why?
| | Aorta | 1 | 2000 | 440 | 0.030 |
Why?
| | Benzothiazoles | 1 | 2016 | 39 | 0.030 |
Why?
| | Image Interpretation, Computer-Assisted | 1 | 2019 | 288 | 0.030 |
Why?
| | Hydrazines | 1 | 2016 | 37 | 0.030 |
Why?
| | Adventitia | 1 | 2016 | 42 | 0.030 |
Why?
| | Carbon | 1 | 2017 | 176 | 0.030 |
Why?
| | Lymph Nodes | 1 | 2019 | 503 | 0.030 |
Why?
| | Membrane Lipids | 1 | 1996 | 82 | 0.030 |
Why?
| | Heat Shock Transcription Factors | 2 | 2006 | 21 | 0.030 |
Why?
| | Phenylurea Compounds | 1 | 2016 | 119 | 0.030 |
Why?
| | Cell Hypoxia | 1 | 2016 | 247 | 0.030 |
Why?
| | Transforming Growth Factor beta | 1 | 2018 | 474 | 0.030 |
Why?
| | Epoxy Compounds | 1 | 2015 | 31 | 0.030 |
Why?
| | Fatty Acid Transport Proteins | 1 | 2015 | 22 | 0.030 |
Why?
| | Gestational Age | 1 | 2019 | 987 | 0.030 |
Why?
| | Stem Cell Niche | 1 | 2015 | 57 | 0.030 |
Why?
| | Carnitine O-Palmitoyltransferase | 1 | 2015 | 49 | 0.030 |
Why?
| | Dihydrolipoyllysine-Residue Acetyltransferase | 1 | 2014 | 6 | 0.030 |
Why?
| | Ketone Oxidoreductases | 1 | 2014 | 7 | 0.030 |
Why?
| | Lipoprotein Lipase | 1 | 2015 | 56 | 0.030 |
Why?
| | Epigenesis, Genetic | 1 | 2020 | 679 | 0.030 |
Why?
| | Sodium Hydroxide | 1 | 2014 | 5 | 0.030 |
Why?
| | Animals, Newborn | 1 | 1997 | 891 | 0.030 |
Why?
| | Membrane Potential, Mitochondrial | 1 | 2014 | 74 | 0.030 |
Why?
| | Half-Life | 1 | 2014 | 155 | 0.030 |
Why?
| | Gene Knockdown Techniques | 1 | 2015 | 333 | 0.030 |
Why?
| | Risk Factors | 1 | 2009 | 10885 | 0.030 |
Why?
| | Precision Medicine | 1 | 2019 | 459 | 0.030 |
Why?
| | Chlorobenzenes | 1 | 2014 | 18 | 0.030 |
Why?
| | Radiopharmaceuticals | 1 | 2015 | 205 | 0.030 |
Why?
| | Superoxides | 1 | 2014 | 198 | 0.030 |
Why?
| | Bone Marrow | 1 | 2015 | 306 | 0.030 |
Why?
| | Pyrroles | 1 | 2015 | 220 | 0.030 |
Why?
| | Maze Learning | 1 | 2014 | 105 | 0.030 |
Why?
| | Recovery of Function | 1 | 2018 | 716 | 0.030 |
Why?
| | Neoplasm Invasiveness | 1 | 2015 | 506 | 0.030 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2020 | 1149 | 0.030 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2014 | 187 | 0.030 |
Why?
| | Mice, Mutant Strains | 1 | 2014 | 302 | 0.020 |
Why?
| | Enzyme Induction | 1 | 2013 | 88 | 0.020 |
Why?
| | beta-Galactosidase | 1 | 2013 | 76 | 0.020 |
Why?
| | Breeding | 1 | 2013 | 63 | 0.020 |
Why?
| | Mice, Inbred A | 1 | 2013 | 48 | 0.020 |
Why?
| | Software | 1 | 2019 | 680 | 0.020 |
Why?
| | Amino Acids, Aromatic | 1 | 2013 | 6 | 0.020 |
Why?
| | Particle Size | 1 | 2014 | 381 | 0.020 |
Why?
| | Antineoplastic Agents, Alkylating | 1 | 2013 | 74 | 0.020 |
Why?
| | Somatomedins | 1 | 2013 | 28 | 0.020 |
Why?
| | Catalysis | 1 | 2014 | 305 | 0.020 |
Why?
| | Vacuoles | 1 | 2013 | 38 | 0.020 |
Why?
| | Staining and Labeling | 1 | 2013 | 153 | 0.020 |
Why?
| | Mitogens | 1 | 2013 | 55 | 0.020 |
Why?
| | Cell Shape | 1 | 2013 | 56 | 0.020 |
Why?
| | Hyperplasia | 1 | 2013 | 177 | 0.020 |
Why?
| | Keratins | 1 | 2013 | 171 | 0.020 |
Why?
| | RNA Interference | 1 | 2014 | 475 | 0.020 |
Why?
| | Immunoenzyme Techniques | 1 | 2013 | 200 | 0.020 |
Why?
| | Tissue Donors | 2 | 2010 | 420 | 0.020 |
Why?
| | Glucose Transporter Type 4 | 1 | 2012 | 39 | 0.020 |
Why?
| | Integrases | 1 | 2013 | 122 | 0.020 |
Why?
| | Adenoviridae | 1 | 2013 | 199 | 0.020 |
Why?
| | Transplantation, Heterologous | 1 | 2013 | 170 | 0.020 |
Why?
| | Risk Assessment | 1 | 2002 | 3747 | 0.020 |
Why?
| | Carcinogens | 1 | 2013 | 123 | 0.020 |
Why?
| | Mitochondrial Proteins | 1 | 2014 | 263 | 0.020 |
Why?
| | Epidermal Growth Factor | 1 | 2013 | 162 | 0.020 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 1 | 2013 | 108 | 0.020 |
Why?
| | Neoplasm Grading | 1 | 2013 | 310 | 0.020 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 1 | 2013 | 174 | 0.020 |
Why?
| | Transcriptome | 1 | 2019 | 1038 | 0.020 |
Why?
| | RNA, Messenger | 2 | 2013 | 2803 | 0.020 |
Why?
| | RNA, Untranslated | 1 | 2013 | 121 | 0.020 |
Why?
| | Long-Term Potentiation | 1 | 2014 | 199 | 0.020 |
Why?
| | Estradiol | 1 | 2015 | 515 | 0.020 |
Why?
| | Mice, Inbred MRL lpr | 1 | 2011 | 36 | 0.020 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2013 | 288 | 0.020 |
Why?
| | Self Administration | 1 | 2012 | 122 | 0.020 |
Why?
| | Colorado | 1 | 2022 | 4553 | 0.020 |
Why?
| | Molecular Chaperones | 1 | 2013 | 199 | 0.020 |
Why?
| | Sucrose | 1 | 2012 | 114 | 0.020 |
Why?
| | Decision Making | 1 | 2019 | 977 | 0.020 |
Why?
| | Bortezomib | 1 | 2011 | 54 | 0.020 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2013 | 749 | 0.020 |
Why?
| | Nestin | 1 | 2010 | 19 | 0.020 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2013 | 223 | 0.020 |
Why?
| | beta Catenin | 1 | 2013 | 254 | 0.020 |
Why?
| | Kidney Glomerulus | 1 | 2011 | 125 | 0.020 |
Why?
| | Intermediate Filament Proteins | 1 | 2010 | 57 | 0.020 |
Why?
| | Urethane | 1 | 2010 | 43 | 0.020 |
Why?
| | Gene Regulatory Networks | 1 | 2013 | 317 | 0.020 |
Why?
| | Receptors, Complement 3d | 1 | 2011 | 129 | 0.020 |
Why?
| | Neutrophils | 2 | 2006 | 1124 | 0.020 |
Why?
| | Immunoblotting | 1 | 2011 | 295 | 0.020 |
Why?
| | Mesenteric Arteries | 1 | 2010 | 17 | 0.020 |
Why?
| | Fatigue | 1 | 2013 | 364 | 0.020 |
Why?
| | HT29 Cells | 1 | 2010 | 37 | 0.020 |
Why?
| | Adenine | 1 | 2013 | 339 | 0.020 |
Why?
| | Kidney Function Tests | 1 | 2010 | 156 | 0.020 |
Why?
| | Cluster Analysis | 1 | 2011 | 500 | 0.020 |
Why?
| | Caspase 3 | 1 | 2011 | 242 | 0.020 |
Why?
| | Hydrogen | 1 | 2010 | 73 | 0.020 |
Why?
| | Proteasome Endopeptidase Complex | 1 | 2011 | 155 | 0.020 |
Why?
| | Ki-67 Antigen | 1 | 2010 | 117 | 0.020 |
Why?
| | Limit of Detection | 1 | 2009 | 92 | 0.020 |
Why?
| | Capillary Permeability | 1 | 2010 | 132 | 0.020 |
Why?
| | Constriction, Pathologic | 1 | 2010 | 249 | 0.020 |
Why?
| | Transplantation Conditioning | 1 | 2010 | 191 | 0.020 |
Why?
| | Citrates | 1 | 2009 | 41 | 0.020 |
Why?
| | Gene Deletion | 1 | 2010 | 391 | 0.020 |
Why?
| | STAT3 Transcription Factor | 1 | 2010 | 206 | 0.020 |
Why?
| | Portal Vein | 1 | 2010 | 117 | 0.020 |
Why?
| | Free Radicals | 1 | 2009 | 105 | 0.020 |
Why?
| | Celecoxib | 1 | 2008 | 42 | 0.020 |
Why?
| | Capecitabine | 1 | 2008 | 56 | 0.020 |
Why?
| | Infusions, Intravenous | 1 | 2010 | 428 | 0.020 |
Why?
| | Bronchoscopy | 2 | 2000 | 227 | 0.020 |
Why?
| | Cell Cycle | 1 | 2011 | 598 | 0.020 |
Why?
| | Mammary Tumor Virus, Mouse | 1 | 2008 | 42 | 0.020 |
Why?
| | Principal Component Analysis | 1 | 2009 | 193 | 0.020 |
Why?
| | Mammary Neoplasms, Animal | 1 | 2008 | 35 | 0.020 |
Why?
| | Dura Mater | 1 | 2008 | 40 | 0.020 |
Why?
| | Genotype | 1 | 2013 | 1852 | 0.020 |
Why?
| | Down-Regulation | 1 | 2010 | 618 | 0.020 |
Why?
| | Aged, 80 and over | 2 | 2013 | 8333 | 0.020 |
Why?
| | Craniotomy | 1 | 2008 | 84 | 0.020 |
Why?
| | Hippocampus | 1 | 2014 | 971 | 0.020 |
Why?
| | Pressure | 1 | 2008 | 226 | 0.020 |
Why?
| | Drug Discovery | 1 | 2009 | 153 | 0.020 |
Why?
| | Ethanol | 1 | 2012 | 631 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2010 | 552 | 0.020 |
Why?
| | Nerve Tissue Proteins | 1 | 2010 | 591 | 0.020 |
Why?
| | Carcinoma | 1 | 2008 | 225 | 0.020 |
Why?
| | United States | 1 | 2024 | 16098 | 0.010 |
Why?
| | Aspartate Aminotransferases | 1 | 2006 | 85 | 0.010 |
Why?
| | Peroxidase | 1 | 2006 | 168 | 0.010 |
Why?
| | Risk | 1 | 2008 | 919 | 0.010 |
Why?
| | Alanine Transaminase | 1 | 2006 | 151 | 0.010 |
Why?
| | Hypoglycemic Agents | 1 | 2015 | 1399 | 0.010 |
Why?
| | Organ Size | 1 | 2006 | 461 | 0.010 |
Why?
| | Membrane Transport Proteins | 1 | 2006 | 154 | 0.010 |
Why?
| | HSP27 Heat-Shock Proteins | 1 | 2005 | 13 | 0.010 |
Why?
| | Child, Preschool | 1 | 2020 | 11853 | 0.010 |
Why?
| | Case-Control Studies | 1 | 2013 | 3623 | 0.010 |
Why?
| | Cytokines | 1 | 2013 | 2067 | 0.010 |
Why?
| | Quercetin | 1 | 2005 | 19 | 0.010 |
Why?
| | Cerebral Cortex | 1 | 2008 | 473 | 0.010 |
Why?
| | Pilot Projects | 1 | 2010 | 1891 | 0.010 |
Why?
| | Dietary Fats | 1 | 2006 | 308 | 0.010 |
Why?
| | Intestinal Mucosa | 1 | 2010 | 675 | 0.010 |
Why?
| | Transplantation, Isogeneic | 1 | 2003 | 17 | 0.010 |
Why?
| | Raffinose | 1 | 2003 | 29 | 0.010 |
Why?
| | Computational Biology | 1 | 2009 | 669 | 0.010 |
Why?
| | Intensive Care Units | 1 | 2010 | 924 | 0.010 |
Why?
| | Allopurinol | 1 | 2003 | 70 | 0.010 |
Why?
| | Organ Preservation Solutions | 1 | 2003 | 46 | 0.010 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2010 | 992 | 0.010 |
Why?
| | Transcriptional Activation | 1 | 2005 | 372 | 0.010 |
Why?
| | Cell Membrane | 1 | 2006 | 707 | 0.010 |
Why?
| | Chromatography, Gas | 1 | 2002 | 30 | 0.010 |
Why?
| | Protein Binding | 1 | 2009 | 2238 | 0.010 |
Why?
| | Adenosine | 1 | 2003 | 255 | 0.010 |
Why?
| | Spectrometry, Mass, Electrospray Ionization | 1 | 2002 | 174 | 0.010 |
Why?
| | Trans-Activators | 1 | 2004 | 396 | 0.010 |
Why?
| | Gene Expression | 1 | 2006 | 1476 | 0.010 |
Why?
| | Lipopolysaccharides | 1 | 2005 | 858 | 0.010 |
Why?
| | Preoperative Care | 1 | 2004 | 380 | 0.010 |
Why?
| | Automation | 1 | 2000 | 104 | 0.010 |
Why?
| | Microchemistry | 1 | 2000 | 19 | 0.010 |
Why?
| | Calibration | 1 | 2000 | 152 | 0.010 |
Why?
| | Receptors, Interleukin-2 | 1 | 2000 | 64 | 0.010 |
Why?
| | Pain Measurement | 1 | 2002 | 561 | 0.010 |
Why?
| | Emulsions | 1 | 2000 | 59 | 0.010 |
Why?
| | Autopsy | 1 | 2000 | 94 | 0.010 |
Why?
| | Blood | 1 | 2000 | 107 | 0.010 |
Why?
| | Postoperative Period | 1 | 2000 | 351 | 0.010 |
Why?
| | Chronic Disease | 1 | 2004 | 1808 | 0.010 |
Why?
| | Prospective Studies | 1 | 2010 | 8057 | 0.010 |
Why?
| | Immune Tolerance | 1 | 2000 | 385 | 0.010 |
Why?
| | Regression Analysis | 1 | 2000 | 1001 | 0.010 |
Why?
| | Recombinant Fusion Proteins | 1 | 2000 | 666 | 0.010 |
Why?
| | Biopsy | 1 | 2000 | 1082 | 0.010 |
Why?
| | Sensitivity and Specificity | 1 | 2000 | 1997 | 0.010 |
Why?
|
|
Serkova's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|